<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;ff=20240312221637
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;ff=20240312221637" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Wed, 13 Mar 2024 02:16:40 +0000</lastbuilddate>
<pubDate>Mon, 11 Mar 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Correction to: Development and Validation of the American Heart Association's PREVENT Equations</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38466792/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240312221637&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Mar 12;149(11):e956. doi: 10.1161/CIR.0000000000001230. Epub 2024 Mar 11.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38466792/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240312221637&v=2.18.0.post9+e462414">38466792</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001230>10.1161/CIR.0000000000001230</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38466792</guid>
<pubDate>Mon, 11 Mar 2024 06:00:00 -0400</pubDate>
<dc:date>2024-03-11</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: Development and Validation of the American Heart Association's PREVENT Equations</dc:title>
<dc:identifier>pmid:38466792</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001230</dc:identifier>
</item>
<item>
<title>Nature and Magnitude of the Benefits of Dapagliflozin and Empagliflozin for Heart Failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38466791/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240312221637&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Mar 12;149(11):839-842. doi: 10.1161/CIRCULATIONAHA.123.068089. Epub 2024 Mar 11.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38466791/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240312221637&v=2.18.0.post9+e462414">38466791</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.068089>10.1161/CIRCULATIONAHA.123.068089</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38466791</guid>
<pubDate>Mon, 11 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>John G F Cleland</dc:creator>
<dc:date>2024-03-11</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Nature and Magnitude of the Benefits of Dapagliflozin and Empagliflozin for Heart Failure</dc:title>
<dc:identifier>pmid:38466791</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.068089</dc:identifier>
</item>
<item>
<title>Dual (Ischemic and Nonischemic) Cardiomyopathy: A Wolf in Sheep's Clothing</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38466790/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240312221637&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Mar 12;149(11):822-824. doi: 10.1161/CIRCULATIONAHA.123.068090. Epub 2024 Mar 11.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38466790/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240312221637&v=2.18.0.post9+e462414">38466790</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.068090>10.1161/CIRCULATIONAHA.123.068090</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38466790</guid>
<pubDate>Mon, 11 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Gladys Juncà</dc:creator>
<dc:creator>Victoria Delgado</dc:creator>
<dc:date>2024-03-11</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Dual (Ischemic and Nonischemic) Cardiomyopathy: A Wolf in Sheep's Clothing</dc:title>
<dc:identifier>pmid:38466790</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.068090</dc:identifier>
</item>
<item>
<title>Letter by Heuts et al Regarding Article, "Fractional Flow Reserve-Guided PCI or Coronary Bypass Surgery for 3-Vessel Coronary Artery Disease: 3-Year Follow-Up of the FAME 3 Trial"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38466789/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240312221637&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Mar 12;149(11):892-893. doi: 10.1161/CIRCULATIONAHA.123.066934. Epub 2024 Mar 11.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38466789/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240312221637&v=2.18.0.post9+e462414">38466789</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066934>10.1161/CIRCULATIONAHA.123.066934</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38466789</guid>
<pubDate>Mon, 11 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Samuel Heuts</dc:creator>
<dc:creator>Patrick O Myers</dc:creator>
<dc:creator>Matthias Siepe</dc:creator>
<dc:date>2024-03-11</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Letter by Heuts et al Regarding Article, "Fractional Flow Reserve-Guided PCI or Coronary Bypass Surgery for 3-Vessel Coronary Artery Disease: 3-Year Follow-Up of the FAME 3 Trial"</dc:title>
<dc:identifier>pmid:38466789</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066934</dc:identifier>
</item>
<item>
<title>Antiarrhythmic Drug Therapy: Where Do We Go From Here?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38466788/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240312221637&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Mar 12;149(11):801-803. doi: 10.1161/CIRCULATIONAHA.123.066989. Epub 2024 Mar 11.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38466788/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240312221637&v=2.18.0.post9+e462414">38466788</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066989>10.1161/CIRCULATIONAHA.123.066989</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38466788</guid>
<pubDate>Mon, 11 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Peter R Kowey</dc:creator>
<dc:creator>Gerald V Naccarelli</dc:creator>
<dc:date>2024-03-11</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Antiarrhythmic Drug Therapy: Where Do We Go From Here?</dc:title>
<dc:identifier>pmid:38466788</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066989</dc:identifier>
</item>
<item>
<title>Are Recommendations That Favor Other Agents Over Angiotensin-Converting Enzyme Inhibitors in Africans With Hypertension Justified?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38466787/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240312221637&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Mar 12;149(11):804-806. doi: 10.1161/CIRCULATIONAHA.123.065887. Epub 2024 Mar 11.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38466787/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240312221637&v=2.18.0.post9+e462414">38466787</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065887>10.1161/CIRCULATIONAHA.123.065887</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38466787</guid>
<pubDate>Mon, 11 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Jonathan G Peter</dc:creator>
<dc:creator>Ntobeko A B Ntusi</dc:creator>
<dc:creator>Mpiko Ntsekhe</dc:creator>
<dc:date>2024-03-11</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Are Recommendations That Favor Other Agents Over Angiotensin-Converting Enzyme Inhibitors in Africans With Hypertension Justified?</dc:title>
<dc:identifier>pmid:38466787</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065887</dc:identifier>
</item>
<item>
<title>Correction to: 2023 Scientific Sessions Abstract 18987</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38466786/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240312221637&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Mar 12;149(11):e959. doi: 10.1161/CIR.0000000000001228. Epub 2024 Mar 11.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38466786/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240312221637&v=2.18.0.post9+e462414">38466786</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001228>10.1161/CIR.0000000000001228</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38466786</guid>
<pubDate>Mon, 11 Mar 2024 06:00:00 -0400</pubDate>
<dc:date>2024-03-11</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: 2023 Scientific Sessions Abstract 18987</dc:title>
<dc:identifier>pmid:38466786</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001228</dc:identifier>
</item>
<item>
<title>End-Stage Heart Failure in Cardiac Sarcoidosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38466785/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240312221637&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Mar 12;149(11):885-887. doi: 10.1161/CIRCULATIONAHA.123.066962. Epub 2024 Mar 11.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38466785/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240312221637&v=2.18.0.post9+e462414">38466785</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066962>10.1161/CIRCULATIONAHA.123.066962</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38466785</guid>
<pubDate>Mon, 11 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Diana Velikanova</dc:creator>
<dc:creator>Pauli Pöyhönen</dc:creator>
<dc:creator>Jukka Lehtonen</dc:creator>
<dc:creator>Piia Simonen</dc:creator>
<dc:creator>Valtteri Uusitalo</dc:creator>
<dc:creator>Tapani Vihinen</dc:creator>
<dc:creator>Kari Kaikkonen</dc:creator>
<dc:creator>Petri Haataja</dc:creator>
<dc:creator>Tuomas Kerola</dc:creator>
<dc:creator>Tuomas T Rissanen</dc:creator>
<dc:creator>Ville Vepsäläinen</dc:creator>
<dc:creator>Aleksi Alatalo</dc:creator>
<dc:creator>Päivi Pietilä-Effati</dc:creator>
<dc:creator>Markku Kupari</dc:creator>
<dc:date>2024-03-11</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>End-Stage Heart Failure in Cardiac Sarcoidosis</dc:title>
<dc:identifier>pmid:38466785</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066962</dc:identifier>
</item>
<item>
<title>Correction to: 2023 Scientific Sessions Abstract 18918</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38466784/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240312221637&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Mar 12;149(11):e958. doi: 10.1161/CIR.0000000000001229. Epub 2024 Mar 11.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38466784/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240312221637&v=2.18.0.post9+e462414">38466784</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001229>10.1161/CIR.0000000000001229</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38466784</guid>
<pubDate>Mon, 11 Mar 2024 06:00:00 -0400</pubDate>
<dc:date>2024-03-11</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: 2023 Scientific Sessions Abstract 18918</dc:title>
<dc:identifier>pmid:38466784</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001229</dc:identifier>
</item>
<item>
<title>Letter by Rodriguez et al Regarding Article, "Fractional Flow Reserve-Guided PCI or Coronary Bypass Surgery for 3-Vessel Coronary Artery Disease: 3-Year Follow-Up of the FAME 3 Trial"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38466783/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240312221637&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Mar 12;149(11):894-895. doi: 10.1161/CIRCULATIONAHA.123.067446. Epub 2024 Mar 11.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38466783/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240312221637&v=2.18.0.post9+e462414">38466783</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067446>10.1161/CIRCULATIONAHA.123.067446</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38466783</guid>
<pubDate>Mon, 11 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Alfredo E Rodriguez</dc:creator>
<dc:creator>Carlos Fernandez-Pereira</dc:creator>
<dc:creator>Juan Mieres</dc:creator>
<dc:date>2024-03-11</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Letter by Rodriguez et al Regarding Article, "Fractional Flow Reserve-Guided PCI or Coronary Bypass Surgery for 3-Vessel Coronary Artery Disease: 3-Year Follow-Up of the FAME 3 Trial"</dc:title>
<dc:identifier>pmid:38466783</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067446</dc:identifier>
</item>
<item>
<title>Response by Zimmermann et al to Letter Regarding Article, "Fractional Flow Reserve-Guided PCI or Coronary Bypass Surgery for 3-Vessel Coronary Artery Disease: 3-Year Follow-Up of the FAME 3 Trial"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38466782/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240312221637&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Mar 12;149(11):896. doi: 10.1161/CIRCULATIONAHA.123.068238. Epub 2024 Mar 11.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38466782/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240312221637&v=2.18.0.post9+e462414">38466782</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.068238>10.1161/CIRCULATIONAHA.123.068238</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38466782</guid>
<pubDate>Mon, 11 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Frederik M Zimmermann</dc:creator>
<dc:creator>Victoria Y Ding</dc:creator>
<dc:creator>William F Fearon</dc:creator>
<dc:date>2024-03-11</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Response by Zimmermann et al to Letter Regarding Article, "Fractional Flow Reserve-Guided PCI or Coronary Bypass Surgery for 3-Vessel Coronary Artery Disease: 3-Year Follow-Up of the FAME 3 Trial"</dc:title>
<dc:identifier>pmid:38466782</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.068238</dc:identifier>
</item>
<item>
<title>Correction to: 2023 Scientific Sessions Abstract 18890</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38466781/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240312221637&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Mar 12;149(11):e957. doi: 10.1161/CIR.0000000000001227. Epub 2024 Mar 11.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38466781/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240312221637&v=2.18.0.post9+e462414">38466781</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001227>10.1161/CIR.0000000000001227</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38466781</guid>
<pubDate>Mon, 11 Mar 2024 06:00:00 -0400</pubDate>
<dc:date>2024-03-11</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: 2023 Scientific Sessions Abstract 18890</dc:title>
<dc:identifier>pmid:38466781</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001227</dc:identifier>
</item>
<item>
<title>Abnormal Progenitor Cell Differentiation and Cardiomyocyte Proliferation in Hypoplastic Right Heart Syndrome</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38466780/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240312221637&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Mar 12;149(11):888-891. doi: 10.1161/CIRCULATIONAHA.123.064213. Epub 2024 Mar 11.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38466780/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240312221637&v=2.18.0.post9+e462414">38466780</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.064213>10.1161/CIRCULATIONAHA.123.064213</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38466780</guid>
<pubDate>Mon, 11 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Yang Yu</dc:creator>
<dc:creator>Cankun Wang</dc:creator>
<dc:creator>Shiqiao Ye</dc:creator>
<dc:creator>Zhaohui Xu</dc:creator>
<dc:creator>Hui Lin</dc:creator>
<dc:creator>Karen Texter</dc:creator>
<dc:creator>Vasudha Shukla</dc:creator>
<dc:creator>Samir Ghadiali</dc:creator>
<dc:creator>Qin Ma</dc:creator>
<dc:creator>Vidu Garg</dc:creator>
<dc:creator>Ming-Tao Zhao</dc:creator>
<dc:date>2024-03-11</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Abnormal Progenitor Cell Differentiation and Cardiomyocyte Proliferation in Hypoplastic Right Heart Syndrome</dc:title>
<dc:identifier>pmid:38466780</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.064213</dc:identifier>
</item>
<item>
<title>2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38466244/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240312221637&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Mar 2:S0735-1097(23)08354-7. doi: 10.1016/j.jacc.2023.12.024. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38466244/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240312221637&v=2.18.0.post9+e462414">38466244</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.12.024>10.1016/j.jacc.2023.12.024</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38466244</guid>
<pubDate>Mon, 11 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Writing Committee</dc:creator>
<dc:creator>Thomas M Maddox</dc:creator>
<dc:creator>James L Januzzi</dc:creator>
<dc:creator>Larry A Allen</dc:creator>
<dc:creator>Khadijah Breathett</dc:creator>
<dc:creator>Sara Brouse</dc:creator>
<dc:creator>Javed Butler</dc:creator>
<dc:creator>Leslie L Davis</dc:creator>
<dc:creator>Gregg C Fonarow</dc:creator>
<dc:creator>Nasrien E Ibrahim</dc:creator>
<dc:creator>JoAnn Lindenfeld</dc:creator>
<dc:creator>Frederick A Masoudi</dc:creator>
<dc:creator>Shweta R Motiwala</dc:creator>
<dc:creator>Estefania Oliveros</dc:creator>
<dc:creator>Mary Norine Walsh</dc:creator>
<dc:creator>Alan Wasserman</dc:creator>
<dc:creator>Clyde W Yancy</dc:creator>
<dc:creator>Quentin R Youmans</dc:creator>
<dc:date>2024-03-11</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee</dc:title>
<dc:identifier>pmid:38466244</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.12.024</dc:identifier>
</item>
<item>
<title>Cardiovascular Management of Patients Undergoing Hematopoietic Stem Cell Transplantation: From Pretransplantation to Survivorship: A Scientific Statement From the American Heart Association</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38465648/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240312221637&amp;v=2.18.0.post9+e462414
      <description>Hematopoietic stem cell transplantation can cure various disorders but poses cardiovascular risks, especially for elderly patients and those with cardiovascular diseases. Cardiovascular evaluations are crucial in pretransplantation assessments, but guidelines are lacking. This American Heart Association scientific statement summarizes the data on transplantation-related complications and provides guidance for the cardiovascular management throughout transplantation. Hematopoietic stem cell...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Mar 11. doi: 10.1161/CIR.0000000000001220. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Hematopoietic stem cell transplantation can cure various disorders but poses cardiovascular risks, especially for elderly patients and those with cardiovascular diseases. Cardiovascular evaluations are crucial in pretransplantation assessments, but guidelines are lacking. This American Heart Association scientific statement summarizes the data on transplantation-related complications and provides guidance for the cardiovascular management throughout transplantation. Hematopoietic stem cell transplantation consists of 4 phases: pretransplantation workup, conditioning therapy and infusion, immediate posttransplantation period, and long-term survivorship. Complications can occur during each phase, with long-term survivors facing increased risks for late effects such as cardiovascular disease, secondary malignancies, and endocrinopathies. In adults, arrhythmias such as atrial fibrillation and flutter are the most frequent acute cardiovascular complication. Acute heart failure has an incidence ranging from 0.4% to 2.2%. In pediatric patients, left ventricular systolic dysfunction and pericardial effusion are the most common cardiovascular complications. Factors influencing the incidence and risk of complications include pretransplantation therapies, transplantation type (autologous versus allogeneic), conditioning regimen, comorbid conditions, and patient age. The pretransplantation cardiovascular evaluation consists of 4 steps: (1) initial risk stratification, (2) exclusion of high-risk cardiovascular disease, (3) assessment of cardiac reserve, and (4) optimization of cardiovascular reserve. Clinical risk scores could be useful tools for the risk stratification of adult patients. Long-term cardiovascular management of hematopoietic stem cell transplantation survivors includes optimizing risk factors, monitoring, and maintaining a low threshold for evaluating cardiovascular causes of symptoms. Future research should prioritize refining risk stratification and creating evidence-based guidelines and strategies to optimize outcomes in this growing patient population.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38465648/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240312221637&v=2.18.0.post9+e462414">38465648</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001220>10.1161/CIR.0000000000001220</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38465648</guid>
<pubDate>Mon, 11 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Salim S Hayek</dc:creator>
<dc:creator>Vlad G Zaha</dc:creator>
<dc:creator>Carmel Bogle</dc:creator>
<dc:creator>Anita Deswal</dc:creator>
<dc:creator>Amelia Langston</dc:creator>
<dc:creator>Seth Rotz</dc:creator>
<dc:creator>Alexi Vasbinder</dc:creator>
<dc:creator>Eric Yang</dc:creator>
<dc:creator>Tochukwu Okwuosa</dc:creator>
<dc:creator>American Heart Association Cardio-Oncology Committee of the Council on Clinical Cardiology and Council on Genomic and Precision Medicine; and the Council on Cardiovascular and Stroke Nursing</dc:creator>
<dc:date>2024-03-11</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Cardiovascular Management of Patients Undergoing Hematopoietic Stem Cell Transplantation: From Pretransplantation to Survivorship: A Scientific Statement From the American Heart Association</dc:title>
<dc:identifier>pmid:38465648</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001220</dc:identifier>
</item>
<item>
<title>Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting in Patients With Left Main Disease With or Without Diabetes: Findings From a Pooled Analysis of 4 Randomized Clinical Trials</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38465592/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240312221637&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In patients with left main disease considered equally suitable for PCI or CABG and with largely low to intermediate SYNTAX scores, diabetes was associated with higher rates of death and cardiovascular events through 5 years. Compared with CABG, PCI resulted in no difference in the risk of death, a lower risk of early stroke regardless of diabetes status, and a higher risk of spontaneous MI and repeat coronary revascularization, with larger late absolute excess risks in patients with...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Mar 11. doi: 10.1161/CIRCULATIONAHA.123.065571. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Diabetes may be associated with differential outcomes in patients undergoing left main coronary revascularization with percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG). The aim of this study was to investigate outcomes in patients with left main disease with and without diabetes undergoing PCI versus CABG.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Individual patient data were pooled from 4 trials (SYNTAX [TAXUS Drug-Eluting Stent Versus Coronary Artery Bypass Surgery for the Treatment of Narrowed Arteries], PRECOMBAT [Bypass Surgery Versus Angioplasty Using Sirolimus-Eluting Stent in Patients With Left Main Coronary Artery Disease], NOBLE [PCI vs. CABG in the Treatment of Unprotected Left Main Stenosis], and EXCEL [Evaluation of XIENCE Versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization]) that randomized patients with left main disease to PCI or CABG. Patients were considered suitable for either approach. Patients were categorized by diabetes status. Kaplan-Meier event rates, Cox model hazard ratios, and interactions were assessed.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 4393 patients, 1104 (25.1%) had diabetes. Patients with diabetes experienced higher rates of 5-year death (158/1104 [Kaplan-Meier rate, 14.7%] versus 297/3289 [9.3%]; <i>P</i>&lt;0.001), spontaneous myocardial infarction (MI; 67/1104 [6.7%] versus 114/3289 [3.7%]; <i>P</i>&lt;0.001), and repeat revascularization (189/1104 [18.5%] versus 410/3289 [13.2%]; <i>P</i>&lt;0.001). Rates of all-cause mortality did not differ after PCI versus CABG in those with (84/563 [15.3%] versus 74/541 [14.1%]; hazard ratio, 1.11 [95% CI, 0.82-1.52]) or without (155/1634 [9.7%] versus 142/1655 [8.9%]; hazard ratio, 1.08 [95% CI, 0.86-1.36; <i>P</i><sub>intHR</sub>=0.87) diabetes. Rates of stroke within 1 year were lower with PCI versus CABG in the entire population, with no heterogeneity based on diabetes status (<i>P</i><sub>intHR</sub>=0.51). The 5-year rates of spontaneous MI and repeat coronary revascularization were higher after PCI regardless of diabetes status (spontaneous MI: 45/563 [8.9%] versus 22/541 [4.4%] in diabetes and 82/1634 [5.3%] versus 32/1655 [2.1%] in no diabetes, <i>P</i><sub>intHR</sub>=0.47; repeat revascularization: 127/563 [24.5%] versus 62/541 [12.4%] in diabetes and 254/1634 [16.3%] versus 156/1655 [10.1%] in no diabetes, <i>P</i><sub>intHR</sub>=0.18). For spontaneous MI and repeat revascularization, there were greater absolute excess risks beyond 1 year in patients with diabetes (4.9% and 9.9%) compared with those without (2.1% and 4.3%; <i>P</i><sub>intARD</sub>=0.047 and 0.016).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In patients with left main disease considered equally suitable for PCI or CABG and with largely low to intermediate SYNTAX scores, diabetes was associated with higher rates of death and cardiovascular events through 5 years. Compared with CABG, PCI resulted in no difference in the risk of death, a lower risk of early stroke regardless of diabetes status, and a higher risk of spontaneous MI and repeat coronary revascularization, with larger late absolute excess risks in patients with diabetes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifiers: NCT01205776, NCT0146651, NCT00422968, and NCT00114972.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38465592/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240312221637&v=2.18.0.post9+e462414">38465592</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065571>10.1161/CIRCULATIONAHA.123.065571</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38465592</guid>
<pubDate>Mon, 11 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Prakriti Gaba</dc:creator>
<dc:creator>Joseph F Sabik</dc:creator>
<dc:creator>Sabina A Murphy</dc:creator>
<dc:creator>Andrea Bellavia</dc:creator>
<dc:creator>Patrick T O'Gara</dc:creator>
<dc:creator>Peter K Smith</dc:creator>
<dc:creator>Patrick W Serruys</dc:creator>
<dc:creator>A Pieter Kappetein</dc:creator>
<dc:creator>Seung-Jung Park</dc:creator>
<dc:creator>Duk-Woo Park</dc:creator>
<dc:creator>Evald H Christiansen</dc:creator>
<dc:creator>Niels R Holm</dc:creator>
<dc:creator>Per H Nielsen</dc:creator>
<dc:creator>Marc S Sabatine</dc:creator>
<dc:creator>Gregg W Stone</dc:creator>
<dc:creator>Brian A Bergmark</dc:creator>
<dc:date>2024-03-11</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting in Patients With Left Main Disease With or Without Diabetes: Findings From a Pooled Analysis of 4 Randomized Clinical Trials</dc:title>
<dc:identifier>pmid:38465592</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065571</dc:identifier>
</item>
<item>
<title>Exercise therapy for chronic symptomatic peripheral artery disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38461405/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240312221637&amp;v=2.18.0.post9+e462414
      <description>All guidelines worldwide strongly recommend exercise as a pillar of the management of patients affected by lower extremity peripheral artery disease (PAD). Exercise therapy in this setting presents different modalities, and a structured programme provides optimal results. This clinical consensus paper is intended for clinicians to promote and assist for the set-up of comprehensive exercise programmes to best advice in patients with symptomatic chronic PAD. Different exercise training protocols...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Mar 10:ehad734. doi: 10.1093/eurheartj/ehad734. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">All guidelines worldwide strongly recommend exercise as a pillar of the management of patients affected by lower extremity peripheral artery disease (PAD). Exercise therapy in this setting presents different modalities, and a structured programme provides optimal results. This clinical consensus paper is intended for clinicians to promote and assist for the set-up of comprehensive exercise programmes to best advice in patients with symptomatic chronic PAD. Different exercise training protocols specific for patients with PAD are presented. Data on patient assessment and outcome measures are narratively described based on the current best evidence. The document ends by highlighting disparities in access to supervised exercise programmes across Europe and the series of gaps for evidence requiring further research.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38461405/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240312221637&v=2.18.0.post9+e462414">38461405</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad734>10.1093/eurheartj/ehad734</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38461405</guid>
<pubDate>Sun, 10 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Lucia Mazzolai</dc:creator>
<dc:creator>Jill Belch</dc:creator>
<dc:creator>Maarit Venermo</dc:creator>
<dc:creator>Victor Aboyans</dc:creator>
<dc:creator>Marianne Brodmann</dc:creator>
<dc:creator>Alessandra Bura-Rivière</dc:creator>
<dc:creator>Sebastien Debus</dc:creator>
<dc:creator>Christine Espinola-Klein</dc:creator>
<dc:creator>Amy E Harwood</dc:creator>
<dc:creator>John A Hawley</dc:creator>
<dc:creator>Stefano Lanzi</dc:creator>
<dc:creator>Juraj Madarič</dc:creator>
<dc:creator>Guillaume Mahé</dc:creator>
<dc:creator>Davide Malatesta</dc:creator>
<dc:creator>Oliver Schlager</dc:creator>
<dc:creator>Arno Schmidt-Trucksäss</dc:creator>
<dc:creator>Chris Seenan</dc:creator>
<dc:creator>Henrik Sillesen</dc:creator>
<dc:creator>Garry A Tew</dc:creator>
<dc:creator>Adriana Visonà</dc:creator>
<dc:date>2024-03-10</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Exercise therapy for chronic symptomatic peripheral artery disease</dc:title>
<dc:identifier>pmid:38461405</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad734</dc:identifier>
</item>
<item>
<title>Sex-related similarities and differences in responses to heart failure therapies</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38459252/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240312221637&amp;v=2.18.0.post9+e462414
      <description>Although sex-related differences in the epidemiology, risk factors, clinical characteristics and outcomes of heart failure are well known, investigations in the past decade have shed light on an often overlooked aspect of heart failure: the influence of sex on treatment response. Sex-related differences in anatomy, physiology, pharmacokinetics, pharmacodynamics and psychosocial factors might influence the response to pharmacological agents, device therapy and cardiac rehabilitation in patients...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Mar 8. doi: 10.1038/s41569-024-00996-1. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Although sex-related differences in the epidemiology, risk factors, clinical characteristics and outcomes of heart failure are well known, investigations in the past decade have shed light on an often overlooked aspect of heart failure: the influence of sex on treatment response. Sex-related differences in anatomy, physiology, pharmacokinetics, pharmacodynamics and psychosocial factors might influence the response to pharmacological agents, device therapy and cardiac rehabilitation in patients with heart failure. In this Review, we discuss the similarities between men and women in their response to heart failure therapies, as well as the sex-related differences in treatment benefits, dose-response relationships, and tolerability and safety of guideline-directed medical therapy, device therapy and cardiac rehabilitation. We provide insights into the unique challenges faced by men and women with heart failure, highlight potential avenues for tailored therapeutic approaches and call for sex-specific evaluation of treatment efficacy and safety in future research.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38459252/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240312221637&v=2.18.0.post9+e462414">38459252</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-00996-1>10.1038/s41569-024-00996-1</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38459252</guid>
<pubDate>Fri, 08 Mar 2024 06:00:00 -0500</pubDate>
<dc:creator>Janice Y Chyou</dc:creator>
<dc:creator>Hailun Qin</dc:creator>
<dc:creator>Javed Butler</dc:creator>
<dc:creator>Adriaan A Voors</dc:creator>
<dc:creator>Carolyn S P Lam</dc:creator>
<dc:date>2024-03-08</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Sex-related similarities and differences in responses to heart failure therapies</dc:title>
<dc:identifier>pmid:38459252</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-00996-1</dc:identifier>
</item>
<item>
<title>CNP Ameliorates Macrophage Inflammatory Response and Atherosclerosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38456298/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240312221637&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Our study reveals that CNP enhanced plaque stability and alleviated macrophage inflammatory responses by promoting HIF-1α degradation, suggesting a novel atheroprotective role of CNP. Enhancing CNP bioactivity may offer a novel pharmacological strategy for treating related diseases.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Mar 8. doi: 10.1161/CIRCRESAHA.123.324086. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: CNP (C-type natriuretic peptide), an endogenous short peptide in the natriuretic peptide family, has emerged as an important regulator to govern vascular homeostasis. However, its role in the development of atherosclerosis remains unclear. This study aimed to investigate the impact of CNP on the progression of atherosclerotic plaques and elucidate its underlying mechanisms.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Plasma CNP levels were measured in patients with acute coronary syndrome. The potential atheroprotective role of CNP was evaluated in ApoE<sup>-/-</sup> mice through CNP supplementation via osmotic pumps, genetic overexpression, or LCZ696 administration. Various functional experiments involving CNP treatment were performed on primary macrophages derived from wild-type and CD36 knockout mice. Proteomics and multiple biochemical analyses were conducted to unravel the underlying mechanism.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: We observed a negative correlation between plasma CNP concentration and the burden of coronary atherosclerosis in patients. In early atherosclerotic plaques, CNP predominantly accumulated in macrophages but significantly decreased in advanced plaques. Supplementing CNP via osmotic pumps or genetic overexpression ameliorated atherosclerotic plaque formation and enhanced plaque stability in ApoE<sup>-/-</sup> mice. CNP promoted an anti-inflammatory macrophage phenotype and efferocytosis and reduced foam cell formation and necroptosis. Mechanistically, we found that CNP could accelerate HIF-1α degradation in macrophages by enhancing the interaction between PHD (prolyl hydroxylase domain-containing protein) 2 and HIF-1α. Furthermore, we observed that CD36 bound to CNP and mediated its endocytosis in macrophages. Moreover, we demonstrated that the administration of LCZ696, an orally bioavailable drug recently approved for treating chronic heart failure with reduced ejection fraction, could amplify the bioactivity of CNP and ameliorate atherosclerotic plaque formation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our study reveals that CNP enhanced plaque stability and alleviated macrophage inflammatory responses by promoting HIF-1α degradation, suggesting a novel atheroprotective role of CNP. Enhancing CNP bioactivity may offer a novel pharmacological strategy for treating related diseases.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38456298/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240312221637&v=2.18.0.post9+e462414">38456298</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.324086>10.1161/CIRCRESAHA.123.324086</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38456298</guid>
<pubDate>Fri, 08 Mar 2024 06:00:00 -0500</pubDate>
<dc:creator>Qiankun Bao</dc:creator>
<dc:creator>Bangying Zhang</dc:creator>
<dc:creator>Lu Zhou</dc:creator>
<dc:creator>Qian Yang</dc:creator>
<dc:creator>Xiaofeng Mu</dc:creator>
<dc:creator>Xing Liu</dc:creator>
<dc:creator>Shiying Zhang</dc:creator>
<dc:creator>Meng Yuan</dc:creator>
<dc:creator>Yue Zhang</dc:creator>
<dc:creator>Jingjin Che</dc:creator>
<dc:creator>Wen Wei</dc:creator>
<dc:creator>Tong Liu</dc:creator>
<dc:creator>Guangping Li</dc:creator>
<dc:creator>Jinlong He</dc:creator>
<dc:date>2024-03-08</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>CNP Ameliorates Macrophage Inflammatory Response and Atherosclerosis</dc:title>
<dc:identifier>pmid:38456298</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.324086</dc:identifier>
</item>
<item>
<title>Rewiring Endothelial Sphingolipid Metabolism to Favor S1P Over Ceramide Protects From Coronary Atherosclerosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38456287/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240312221637&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: These data demonstrated that hemodynamic stress induced a protective rewiring of sphingolipid metabolism, favoring S1P over ceramide. NOGO-B deletion sustained the rewiring of sphingolipid metabolism toward S1P protecting EC from activation under hemodynamic stress and refraining coronary atherosclerosis. These findings also set forth the foundation for sphingolipid-based therapeutics to limit atheroprogression.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Mar 8. doi: 10.1161/CIRCRESAHA.123.323826. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Growing evidence correlated changes in bioactive sphingolipids, particularly S1P (sphingosine-1-phosphate) and ceramides, with coronary artery diseases. Furthermore, specific plasma ceramide species can predict major cardiovascular events. Dysfunction of the endothelium lining lesion-prone areas plays a pivotal role in atherosclerosis. Yet, how sphingolipid metabolism and signaling change and contribute to endothelial dysfunction and atherosclerosis remain poorly understood.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We used an established model of coronary atherosclerosis in mice, combined with sphingolipidomics, RNA-sequencing, flow cytometry, and immunostaining to investigate the contribution of sphingolipid metabolism and signaling to endothelial cell (EC) activation and dysfunction.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: We demonstrated that hemodynamic stress induced an early metabolic rewiring towards endothelial sphingolipid de novo biosynthesis, favoring S1P signaling over ceramides as a protective response. This finding is a paradigm shift from the current belief that ceramide accrual contributes to endothelial dysfunction. The enzyme SPT (serine palmitoyltransferase) commences de novo biosynthesis of sphingolipids and is inhibited by NOGO-B, an ER membrane protein. Here, we showed that NOGO-B is upregulated by hemodynamic stress in myocardial EC of ApoE<sup>-</sup><sup>/-</sup> mice and is expressed in the endothelium lining coronary lesions in mice and humans. We demonstrated that mice lacking NOGO-B specifically in EC (Nogo-A/B<sup>ECKO</sup>ApoE<sup>-/-</sup>) were resistant to coronary atherosclerosis development and progression, and mortality. Fibrous cap thickness was significantly increased in Nogo-A/B<sup>ECKO</sup>ApoE<sup>-/-</sup> mice and correlated with reduced necrotic core and macrophage infiltration. Mechanistically, the deletion of NOGO-B in EC sustained the rewiring of sphingolipid metabolism towards S1P, imparting an atheroprotective endothelial transcriptional signature.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: These data demonstrated that hemodynamic stress induced a protective rewiring of sphingolipid metabolism, favoring S1P over ceramide. NOGO-B deletion sustained the rewiring of sphingolipid metabolism toward S1P protecting EC from activation under hemodynamic stress and refraining coronary atherosclerosis. These findings also set forth the foundation for sphingolipid-based therapeutics to limit atheroprogression.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38456287/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240312221637&v=2.18.0.post9+e462414">38456287</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323826>10.1161/CIRCRESAHA.123.323826</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38456287</guid>
<pubDate>Fri, 08 Mar 2024 06:00:00 -0500</pubDate>
<dc:creator>Onorina Laura Manzo</dc:creator>
<dc:creator>Jasmine Nour</dc:creator>
<dc:creator>Linda Sasset</dc:creator>
<dc:creator>Alice Marino</dc:creator>
<dc:creator>Luisa Rubinelli</dc:creator>
<dc:creator>Sailesh Palikhe</dc:creator>
<dc:creator>Martina Smimmo</dc:creator>
<dc:creator>Yang Hu</dc:creator>
<dc:creator>Maria Rosaria Bucci</dc:creator>
<dc:creator>Alain Borczuk</dc:creator>
<dc:creator>Olivier Elemento</dc:creator>
<dc:creator>Julie K Freed</dc:creator>
<dc:creator>Giuseppe Danilo Norata</dc:creator>
<dc:creator>Annarita Di Lorenzo</dc:creator>
<dc:date>2024-03-08</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Rewiring Endothelial Sphingolipid Metabolism to Favor S1P Over Ceramide Protects From Coronary Atherosclerosis</dc:title>
<dc:identifier>pmid:38456287</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323826</dc:identifier>
</item>
<item>
<title>Thrombocytopenia Independently Leads to Changes in Monocyte Immune Function</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38456277/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240312221637&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Thrombocytopenia immune programs monocytes in a manner that may lead to immune dysfunction in the context of sepsis. This is the first demonstration that sterile, endogenous cell interactions between resting platelets and monocytes regulate monocyte metabolism and pathogen responses, demonstrating platelets to be immune rheostats in both health and disease.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Mar 8. doi: 10.1161/CIRCRESAHA.123.323662. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: While platelets have well-studied hemostatic functions, platelets are immune cells that circulate at the interface between the vascular wall and white blood cells. The physiological implications of these constant transient interactions are poorly understood. Activated platelets induce and amplify immune responses, but platelets may also maintain immune homeostasis in healthy conditions, including maintaining vascular integrity and T helper cell differentiation, meaning that platelets are central to both immune responses and immune quiescence. Clinical data have shown an association between low platelet counts (thrombocytopenia) and immune dysfunction in patients with sepsis and extracorporeal membrane oxygenation, further implicating platelets as more holistic immune regulators, but studies of platelet immune functions in nondisease contexts have had limited study.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We used in vivo models of thrombocytopenia and in vitro models of platelet and monocyte interactions, as well as RNA-seq and ATAC-seq, to mechanistically determine how resting platelet and monocyte interactions immune program monocytes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Circulating platelets and monocytes interact in a CD47-dependent manner to regulate monocyte metabolism, histone methylation, and gene expression. Resting platelet-monocyte interactions limit TLR (toll-like receptor) signaling responses in healthy conditions in an innate immune training-like manner. In both human patients with sepsis and mouse sepsis models, thrombocytopenia exacerbated monocyte immune dysfunction, including increased cytokine production.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Thrombocytopenia immune programs monocytes in a manner that may lead to immune dysfunction in the context of sepsis. This is the first demonstration that sterile, endogenous cell interactions between resting platelets and monocytes regulate monocyte metabolism and pathogen responses, demonstrating platelets to be immune rheostats in both health and disease.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">REGISTRATION: URL: https://www.biorxiv.org/content/10.1101/2023.05.10.540214v1.full; Unique identifier: XXX.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38456277/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240312221637&v=2.18.0.post9+e462414">38456277</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323662>10.1161/CIRCRESAHA.123.323662</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38456277</guid>
<pubDate>Fri, 08 Mar 2024 06:00:00 -0500</pubDate>
<dc:creator>Chen Li</dc:creator>
<dc:creator>Sara K Ture</dc:creator>
<dc:creator>Benjamin Nieves-Lopez</dc:creator>
<dc:creator>Sara K Blick-Nitko</dc:creator>
<dc:creator>Preeti Maurya</dc:creator>
<dc:creator>Alison C Livada</dc:creator>
<dc:creator>Tyler J Stahl</dc:creator>
<dc:creator>Minsoo Kim</dc:creator>
<dc:creator>Anthony P Pietropaoli</dc:creator>
<dc:creator>Craig N Morrell</dc:creator>
<dc:date>2024-03-08</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Thrombocytopenia Independently Leads to Changes in Monocyte Immune Function</dc:title>
<dc:identifier>pmid:38456277</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323662</dc:identifier>
</item>





























</channel>
</rss>